An intended consequence of the significant investment to characterize the mammalian genome, and its alterations in neoplastic diseases, has been the discovery and commercialization of new approaches to anticancer therapy. As a result, the list of available targets, formerly directed against the processes of DNA replication and mitosis, or in hormonal regulation of growth of tissue, has been dramatically extended. Many of the newer targets represent normal or aberrant signaling pathways, and are present within the cancer cell as second messengers, on its surface (as receptors), or in the external milieu (as ligands). These targets are, therefore, important to the cancer cell phenotype, and affect proliferation, differentiation, and death options for the cell. Another group of targets encompass the cancer cell's relationship to the tissue environment (both stroma and nonneoplastic cells). These targets involve interactions with blood supply (angiogenesis), immune function (evasion), and matrix (invasion and metastasis). Thus, most targets are directly or indirectly critical to some aspect of cancer cell physiology, although a few additional targets are being approached as localization signals for the delivery of otherwise less specific chemotherapeutic or radiotherapeutic agents. The development of new therapeutic approaches has expanded the scope of research required to characterize the mechanism of action for anticancer agents in preclinical models and in clinical trials. In preclinical research, mechanism of action studies have supported the selection of therapeutic agents, appropriate models of efficacy, and experimental design, as well as rational characterization and prediction of nontumor (host) effects. In clinical research, mechanism of action studies have supported the identification of surrogate markers of efficacy (critical for determining adequacy of dose and latency of response), and the selection of patient subpopulations and tumor subtypes most likely to exhibit clinical responses. Finally, information on mechanism of action may suggest strategies for combination therapies and predict potential mechanisms of disease resistance to therapy.
INTRODUCTION
Cancer is a major cause of morbidity and mortality in developed countries. A generic term, cancer is often used to denote a group of malignant neoplastic diseases originating in a variety of sites, tissues, and cell types. For certain types of cancer, scientific advances have enabled prevention strategies that have reduced the incidence of disease. For certain other types of cancer, scientific strategies have enabled earlier detection approaches that have enabled success of existing therapeutics which are nonspecific in nature, such as surgical ablation, radiation, and cytotoxic drugs. Despite these successes, several cancers present patients with ineffective treatment options, and impaired quality of life and survival.
A major effort in cancer research is underway to understand the molecular and cellular biology of the cancer cell phenotype. Estimated spending on research and development of anti-cancer therapeutic agents by the pharmaceutical industry and government is difficult to precisely measure. Approximately $56 billion (U.S.) was spent for all pharmaceutical research and development in 2002, with $32 billion from industry and $24 billion from the U.S. National Institutes of Health, as cited by the Pharmaceutical Research and Manufacturers of America (PhRMA, 2003) . If 20% of the effort was focused on cancer (instead of other diseases), the combined direct investment of industry and government would exceed $10 billion. The U.S. National Cancer Institute (NCI) 2002 budget totaled approximately $4.2 trillion, of which $1.0 trillion was designated as "Treatment Research" and $0.7 trillion was designated as "Cancer Biology" (National Cancer Institute, 2002) . The NCI investment, while not directly designated for new therapeutic agents, undoubtedly supports the basic research that leads to identification and characterization of new strategic targets for the treatment of cancer. The sizeable efforts by government and industry in research and development of new therapeutic agents that target the cancer cell phenotype indicate the potential utility of investigation into the mechanism of action of these anti-cancer agents.
Analysis of Cell Phenotype in Cancer-The Search for Targeted Therapeutics
Many of the characteristics of cancer are manifestations of abnormal changes in the physiology of cancer cells. A recent review presented a unified concept of these changes as steps, acquired by a lineage of cells, resulting in malignant growth (Hanahan and Weinberg, 2000) . These changes (summarized in Table 1 ) include: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion/metastasis. These physiological changes result from the stepwise accumulation of heritable genetic alterations, and for any change, a different gene or group of genes might be involved. Even in cancers of the same cell type and tissue of origin, a different combination of genetic alterations might account for similar physiological changes that contribute to the development of cancer.
The biochemical events that lead to critical changes in the physiology of cancer cells are becoming the newest targets for anticancer therapeutics. Even when it is not possible to permanently inhibit or modify the biochemical events, a (Hanahan and Weinberg, 2000) . Insensitivity to antigrowth signals  Evading apoptosis  Limitless replicative potential  Sustained angiogenesis  Tissue invasion and metastasis reversible modification of the biochemical events could theoretically arrest or reverse malignant growth. This possibility has lead to a shift in the paradigm for defining the objective cancer therapy. The former goal of cancer therapy was to eliminate every malignant cell from the patient. The new goal suggested by the approach of altering specific biochemical pathways is that cancer will be managed as a chronic disease by reversing the physiological changes in cancer cells, rather than attempting to directly eliminate every malignant cell from the patient.
Self-sufficiency in growth signals
As selected biochemical events responsible for critical changes in the physiology of cancer cells are targeted, the characterization of the genetic changes in cancer cells is no longer only of interest for the study of carcinogenesis or for prognostic evaluation. Rather, the molecular diagnostic work-up of each patient's disease becomes necessary for selection of relevant targeted therapeutics and predicting response. In fact, the subclassification of cancer, using molecular markers, is critical to development of new therapeutic strategies and enhancing the value of clinical studies. Molecular subclassification can be the impetus to shift commercialization strategies, from the "blockbuster" strategy (1 drug, many patients) to "personalized medicine" strategy (many drugs, many patients, Augen, 2002) .
The discovery and development of new cancer therapeutics depends on experimental models involving in vitro and in vivo (animal) preclinical studies. This process is best informed when a mechanism of action is anticipated and directly evaluated in preclinical and clinical studies. Therefore, information regarding mechanism of action can confirm hypotheses regarding therapeutic efficacy, as well as expedite the development and testing of new hypotheses when the magnitude of efficacy is less than expected. The use of information regarding mechanism of action can facilitate: 1) biomarker development to monitor response to therapy; 2) stratification of patients to more precisely define therapeutic efficacy; 3) development of rationale for combination regimens; and 4) prediction and possibly prevention of acquired resistant disease.
A review of literature shows that each of the 6 physiological changes that lead to malignant growth is represented among targeted therapies currently under investigation. For the purposes of this review, however, therapeutics targeting the biochemistry of 2 of these alterations will be considered: selfsufficiency in growth signals, and sustained angiogenesis.
Mechanism of Action for Therapies Against Self-Sufficiency in Growth Signals
Recent advances in the understanding of how cancer cells achieve self-sufficiency in growth signals are leading new therapeutics for treatment of cancer (3). Generally, the tar-gets of these therapeutics include either 1) the membranelocated receptor or its associated extracellular growth factor, or 2) the intracellular signal transduction pathways that link the membrane-located receptor activation to the effectors of cell growth.
Examples of receptors that have been proposed as therapeutic targets include the Epidermal Growth Factor Receptor (EGFR) family members, Platelet-Derived Growth Factor Receptor (PDGFR), c-met, Insulin-Like Growth Factor Receptor (IGFR) family members, c-kit, Flt-3, and others (Traxler, 2003) . It is possible to target these receptors by blocking their enzymatic activity that is required for initiation of intracellular signaling (with therapeutics that bind to the intracellular portion of the receptor), or by blocking the interaction of the relevant ligand (or ligands) with the receptor (with therapeutics that bind to ligand or extracellular portion of the receptor).
The intracellular signaling pathways that propagate the initiation of signaling from membrane located receptors to effectors include several potential therapeutic targets, including ras, raf, Mitogen-Activated Protein Kinases such as Extracellular-signal Regulated Kinase (ERK) 1/2, and MAPK/ERK Kinase (MEK) 1/2 (Sebolt-Leopold, 2000) . An example of a non-receptor target is BCR-Abl, a mutated tyrosine kinase that is constitutively activated in chronic myelogenous leukemia. The drug imatinib mesylate that blocks the receptor tyrosine kinase activity responsible for initiation of signaling was recently commercialized for therapy (Nimmanapalli and Bhalla, 2002) . It should be noted that the mechanism of action for imatinib mesylate appears to depend on inhibition of BCR-Abl's anti-apoptotic effect. Another example of strategies to inhibit these intracellular targets includes the application of farnesyl transferase inhibitors (FTIs), since ras activity depends on its localization to the cell membrane, which requires post-translational farnesylation of ras protein (Awada et al., 2002) . Several FTIs have entered clinical trials, although an approved therapeutic agent that targets these molecules is not yet available.
The Human EGFR (also known as erbB or HER) family of membrane-located growth factor receptors has yielded some key targets for therapeutic intervention in cancer (Ritter and Arteaga, 2003 ). An antibody therapy against HER2 (erbB2) has been approved and commercialized (Dillman, 1999) . A certain fraction of breast cancers have over-expression of HER2, typically as the result of gene amplification, and this finding is associated with a poorer prognosis (Kurebayashi, 2001) . In a significant percentage of patients with HER2overexpressing breast cancers, administration of this anti-HER2 antibody (trastuzumab) increases the rate of response to chemotherapy and improves survival. Interestingly, the mechanism of action of trastuzumab has not been resolved, and the natural ligand of HER2 is unknown.
Preclinical and clinical research is ongoing for therapeutic agents that target EGFR (HER1 or erbB1) . This receptor has 3 known natural ligands: Epidermal Growth Factor, Transforming Growth Factor-α, and amphiregulin. The role of EGFR in cancer was suggested nearly 20 years ago, when sequence homology was identified between EGFR and the retroviral oncogene v-erbB (Lin et al., 1984; Kris et al., 1985) . Clinical research on this therapeutic target has involved different antibodies against 118 CATTLEY AND RADINSKY TOXICOLOGIC PATHOLOGY EGFR, including C225 (Kies and Harari, 2002; Reynolds, 2002) , with more recent trial results reported in 2003 (Cunningham et al., 2003) . In the same year, the U.S. F.D.A. approved gefitinib, a tyrosine kinase receptor inhibitor of EGFR, as monotherapy for patients with non-small cell lung cancer who have failed both platinum-based and docataxel therapies (Muhsin et al., 2003) .
The rationale behind therapeutics that target EGFR is based on the role of EGFR in promoting epithelial cell growth and survival (Arteaga, 2002) . The expression of EGFR has been demonstrated by immunohistochemistry in a variety of epithelial cancers, including head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, lung cancer, and prostate cancer (Spaulding and Spaulding, 2002; Ritter and Arteaga, 2003) . In some of these cancers (head and neck, colorectal, and prostate), higher levels of expression have been linked to poorer prognosis. EGFR is also expressed in glioblastoma multiforme (GBM), a malignant glial cell neoplasm of the central nervous system. In approximately 30% of GBM, the EGFR gene is amplified. In some GBM, the EGFR gene may contain a mutation that results in ligand-independent constitutive activation (Wong et al., 1992; Nishikawa et al., 1994) .
The mechanism of action of the monoclonal antibody C225 as an anticancer therapeutic was characterized in human L3.6pl pancreatic cells in cell culture and in tumor xenografts in immunodeficient mice (Bruns et al., 2000) . In cell culture, L3.6pl cells express EGFR, and it is activated by EGF via autophosphorylation of tyrosine sites in the EGFR. This EGF-induced autophosphorylation was blocked by the addition of C255 to the culture medium. Tumor xenografts comprised of L3.6pl cells growing in murine pancreas expressed EGFR by immunohistochemistry. The EGFR in the L3.6pl cells was autophosphorylated, as demonstrated by immunohistochemistry using a primary antibody that specifically binds to phospho-EGFR. Administration of C225 to the mice resulted in a loss immunohistochemically detected phospho-EGFR. This response to C225 was associated with a reduction in incidence of detectable tumors and a reduction in volume of tumor in L3.6pl-grafted mice. An analysis of L3.6pl xenografts for frequency of proliferation (as detected by PCNA immunostaining) and apoptosis (as detected by Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labeling, abbreviated TUNEL) was performed to evaluate the mechanism of reduced tumor incidence and size. There was a statistically significant decrease (∼3-fold) in frequency of PCNA-positive cells, and an increase (∼5-fold), although not statistically significant, in frequency of TUNEL-positive cells. These findings indicate that C225 caused a reduction in incidence and size of L3.6pl xenografts by reducing the rate of proliferation and possibly also by increasing the rate of apoptosis.
The expression of EGFR has been analyzed in a series of tumor xenografts resulting from subcutaneous injection of 6 different human cancer cell lines into immunodeficient mice (Sirotnak et al., 2000) . Results obtained by detected intensity of immunohistochemical staining of EGFR in tissue sections and by the amount of reaction product from RT-PCR of RNA isolated from tissue homogenates were in agreement and varied. The response of xenografts generated by the same six human cancer cell lines to varying doses of gefitinib was determined by measurement of tumor mass. A dose-related response was observed in each type of tumor xenograft, and the magnitude of response at each dose of gefitinib was directly related to the level of EGFR expression for each type of xenograft.
The association of response to therapeutics that target EGFR and level of EGFR expression has been variably evaluated in human clinical trials. In phase I and II studies of gefitinib, EGFR expression status was not a criterion for patient selection . Post-hoc analysis of EGFR expression by immunohistochemical staining indicated that response of patients with non-small cell lung cancer to gefitinib was not predicted by EGFR expression levels. In a separate Phase II study of another EGFR tyrosine kinase inhibitor, erlotinib, objective tumor response and stable disease were not associated with more EGFR-positive cells or more intense EGFR staining (Sorbera et al., 2003; Grunwald and Hidalgo, 2003) .
One of the effects of EGFR-targeted therapies has been the development of skin lesions as the result of treatment. Effects of both the EGFR TK inhibitor gefitinib and the anti-EGFR antibody C225 were analyzed in skin biopsies that documented the presence of acneiform folliculitis (Busam et al., 2001; Albanell et al., 2002) . In the case of gefitinib, immunohistochemical comparison of skin biopsies collected 14 days before and 28 days after initiation of treatment confirmed effects of gefitinib on EGFR signaling, including consistent expression of EGFR before and after initiation of therapy, as well as 1) reduced EGFR phosporylation, 2) decreased activation of MAPK, 3) increased frequency of the cyclin-dependent kinase inhibitor p27, and 4) decreased frequency of the proliferation marker Ki67 after initiation of therapy . In addition, there was both increased keratinocyte apoptosis after initiation of therapy and increased thickness of stratum corneum after initiation of gefitinib therapy. Results of analysis of skin biopsies before and after initiation of C225 therapy were similar in that increased frequency of the cyclin-dependent kinase inhibitor p27 was observed (Busam et al., 2001) . These findings suggested that immunohistochemical results of serial skin biopsies might predict antitumor responses in patients. Recent preliminary evidence suggests that the appearance of skin rash may be a predictor of survival in patients with a variety of cancers treated with either erlotinib (Clark et al., 2003) or C225 (Saltz et al., 2003) . This indicates that presence of skin rash at least predicts that sufficient dosing with anti-EGFR agent has been achieved.
The immunohistochemical assessment of the mechanism of anti-EGFR response in skin suggests that similar markers might be evaluated in tumor tissue. The need to perform serial tumor biopsies has several practical as well as theoretical limitations, but appears to be the next strategy for characterizing the mechanism of action of EGFR-targeted therapies. As an intermediate strategy, the effect of gefitinib was recently evaluated in primary tumor xenografts in immunodeficient mice using fragments of freshly excised breast tissue samples containing either normal breast parenchyma or ductal carcinoma in situ (Chan et al., 2002) . After 14 days of treatment, the dose response to gefitinib was evaluated by analysis of Vol. 32(Suppl. 1), 2004 CANCER THERAPEUTICS 119 the proliferation marker Ki67. Although both normal breast parenchymal cells and DCIS cells responded to gefitinib by decreasing the frequency of Ki67 staining, the shape of the dose response indicated that normal breast parenchymal cells were more responsive to gefitinib treatment. These results indicate that a proliferation marker such as Ki67 might be applied to serial biopsies of DCIS or other cancers, to understand the mechanism of action of EGFR-targeted therapy and possibly predict objective response to therapy. The characterization of mechanism of action of EGFRtargeted therapy continues to be a key focus of ongoing clinical programs. As EGFR as well as other growth factor pathways are being investigated for utility as targets of therapy, efforts to understand the mechanism of tumor response will continue to evolve.
Mechanism of Action for Therapies Against Sustained Angiogenesis
The critical role of sustained angiogenesis in cancer progression has been accepted for some time, although antiangiogenic therapies are relatively new in terms of numbers of agents being developed and commercialized for treatment of cancer. Angiogenesis involves various steps, including the proliferation and sprouting of endothlelial cells as well as the survival and maturation of newly formed blood vessels. Sustained angiogenesis is necessary to support growth of primary and metastatic tumors (Folkman, 1971) .
A variety of signaling molecules and pathways have been implicated in tumor angiogenesis and proposed as possible targets for cancer therapeutics (Madhusudan and Harris, 2002) . These include ligand/receptor pairs such as Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor 2 (VEGFR-2), as well as Angiopoietin 2 (Ang2)/Tyrosine kinase with Ig and Epidermal growth factor homology 2 (Tie2). Additional factors proposed as anti-angiogenesis targets include endostatin, basic Fibroblast Growth Factor, integrins, Ets-1, and endoglin. Several of these factors have been implicated in the proliferation and survival of vascular endothelial cells.
One target that has reached the stage of clinical development, VEGF, was first identified in 1989 (Leung et al., 1989) . VEGF is secreted by tumor cells, in a hypoxia-inducible manner, and it binds to VEGFR-2 to increase proliferation and survival of vascular endothelial cells. Recently reported clinical trial results have demonstrated that treatment with bevacizumab, an anti-VEGF monoclonal antibody, in combination with chemotherapy resulted in an improvement in survival of patients with colorectal cancer beyond that seen with chemotherapy alone (McCarthy, 2003) . These results with bevacizumab are the first evidence that a therapy targeting a key pathway in sustained angiogenesis can result in improved survival.
A variety of strategies have been employed to characterize the mechanism of action of therapies that target sustained angiogenesis. Studies of the mechanism of action of SU5416, a VEGFR-2 receptor tyrosine kinase inhibitor, have been conducted in a model of liver metastasis based on intrasplenic injection of murine colon cancer-derived cells (CT26 cell line) (Shaheen et al., 1999) . Upon administration of SU5416 from 4-22 days after injecting the CT26 cells, the frequency of liver metastases and liver weight (an indicator of metastatic burden) were reduced. One indicator of the anti-angiogenic effect of SU5416 was the reduction in the numbers of blood vessels detected by positive immunohistochemical staining for CD31, an endothelial cell marker, in the liver lesions. Another indicator of the anti-angiogenic effect of SU5416 was the increased frequency of apoptotic endothelial cells in the liver lesions, detected by colocalization of CD31 with positive nuclei for TUNEL. These findings are strongly suggestive of an anti-angiogenic mechanism of action, but do not entirely distinguish between a direct effect of SU5416 on VEGFR-2 from an indirect effect of SU5416 on tumor cells that impairs production of VEGF or other pro-angiogenic factors.
Vascular endothelial cells are often found in close association with pericytes (Schlingemann et al., 1991) . Pericytes are identified in tissue sections by positive immunohistochemical staining for smooth muscle actin (SMA). Recent evidence indicating that pericytes may influence the response of vascular endothelial cells to anti-angiogenic agents has been obtained using a tumor allograft model resulting from subcutaneous injection of K1735 murine melanoma cells in C57Bl/6 mice (Gee et al., 2003) . Vascular endothelial cells and pericytes were analyzed in tissue sections using von Willebrands Factor (vWF) and SMA, respectively. Treatment of mice with the angiogenesis inhibitor recombinant murine Interleukin-12 (IL-12) for 3 weeks resulted in preferential reduction in the frequency of pericyte-deficient blood vessels (SMA-negative, CD31-positive). In contrast, there was no IL-12 treatmentrelated reduction in the frequency of pericyte-associated blood vessels (SMA-positive, CD31-positive). In addition, the frequency of endothelial cell apoptosis was evaluated using TUNEL, with increased apoptosis observed in pericytedeficient blood vessels, but not in pericyte-associated blood vessels. These findings indicate that a mechanism of resistance for some therapies directed against sustained angiogenesis may arise from pericyte-endothelial interactions, and that targeting pericytes directly might improve responsiveness to endothelial cell-associated targets.
It is possible that the mechanism of action for some antiangiogenic therapies may involve direct effects on both endothelial cells and pericytes. In a study using a colon cancer liver metastasis model in mice, treatment of mice with the alphaVbeta3 integrin antagonist S247 reduced the frequency of liver metastasis (Reinmuth et al., 2003) . When mice were treated with S247 from 7-21 days after intrasplenic injection of CT26 cells, the overall frequency of blood vessels in tumors, identified by CD31 immunostaining, was reduced. The frequency of apoptotic endothelial cells in tumors, identified by colocalization of CD31 and TUNEL, was increased by S247 treatment. In the same tumors, the remaining CD31postive blood vessels were evaluated for pericyte association by co-localization of SMA. S247 treatment reduced the percentage of blood vessels with pericyte association. These results indicate that the anti-angiogenic effect of the alphaVbeta3 integrin antagonist S247 might be attributable to direct effects on both endothelial cells and pericytes.
The mechanism of action of therapeutic agents that block sustained angiogenesis suggests at least one possible mode of tumor resistance to anti-angiogenic therapies might be that 120 CATTLEY AND RADINSKY TOXICOLOGIC PATHOLOGY of increased invasiveness. In other words, blockade of the angiogenesis option may result in invasion of adjacent host tissues, with oxygen and nutrient supply depending of coopted existing blood vessels rather than new blood vessels. Antiangiogeneic therapies induce tumor tissue hypoxia, which itself has been proposed as a potential accelerator of cancer progression (Bottaro and Liotta, 2003) . In a recent immunohistochemical study of breast cancer samples, the expression of c-met was found to be localized in cancer cells at sites having expression of Hypoxia Inducible Factor-(HIF-)1a, a transcription factor that is up-regulated by hypoxia, but differentially located from blood vessels labeled using CD31 (Pennacchietti et al., 2003) . Since activation of c-met by its ligand, Hepatocyte Growth Factor (HGF), is known to induce motility and invasion in vitro, the activation of c-met in the cancer cells could increase invasiveness of cancer cells and support disease progression and metastasis. The characterization of mechanism of action of antiangiogenic therapy continues to be a key focus of ongoing clinical research programs. As endothelial cell-and pericytespecific factors are being investigated for utility as targets of therapy, efforts and means to understand the mechanism of action in tumor response will continue to evolve.
CONCLUSIONS
The use of technological advances in molecular and cellular biology as well as bioinformatics have resulted in identification and characterization of a variety of new targets for anti-cancer therapies. Of the 6 general phenotypes that enable the development and progression of malignant disease (Table 1 , Hanahan and Weinberg, 2000) , the achievement of self-sufficiency in growth factor signaling and sustained angiogenesis are being translated into clinical therapeutic agents progressing in development and commercialization. Efforts to gain an understanding of the mechanism of action of these targeted therapeutic agents will enable the stratification of patients and the identification of biomarkers to facilitate clinical research. In addition, understanding the mechanism of action will undoubtedly support and optimize rational combination therapies and anticipate potential resistance mechanisms. As a result, continuing research on mechanism of action will be needed for successful translation of basic research to clinically useful anti-cancer therapies.
